Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.

Front Pharmacol · 2025 · PMC12684286 · PMID 41368577

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In the Weibull analysis for pemafibrate, the shape parameter (β) was 1.59 [1.17–2.56], indicating an increasing trend in ADE reporting with continued pemafibrate use.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.